Zoetis Stock: Shares Tumble 13.78% After Forecast Revision
Zoetis experienced a sharp correction on Tuesday, November 4, with shares dropping 13.78% to close at $124.46. The animal health company announced a downward revision of its annual revenue forecast, attributing this adjustment to sluggish demand for its treatments and vaccines. The market responded with a massive sell-off throughout the session.
Significant Drop in Zoetis Shares
Zoetis shares closed on Tuesday, November 4 at $124.46, down 13.78% from the previous day. This drop of over 13% is among the steepest recorded for the stock in 2025. In comparison, the S&P 500 index rose by 0.36% on the same day, reaching 6,740.28 points, highlighting a significant divergence in performance between the stock and the broader market. Trading volume reached 11.92 million shares, accounting for 2.69% of Zoetis's total market capitalization. This high volume of trade reflects the scale of investor reaction to the company's announcements, with a capital turnover rate exceeding usual averages. On an annual basis, the situation appears much more concerning. Over the past twelve months, Zoetis's stock has fallen by 28.95%, while the S&P 500 has gained 18.33%. This divergence underscores the challenges in the animal health sector, which are more pronounced than those affecting the overall US stock market. On a weekly basis, the stock has shown a decline of 14.41%, indicating continued pressure on prices since the beginning of the week.
Reasons Behind Tuesday's Debacle
The debacle recorded on Tuesday can be traced back to a major announcement made in pre-market hours. Zoetis revised its revenue forecast range for 2025 downwards, from $9.45 to $9.60 billion to $9.40 to $9.48 billion. This adjustment follows a third quarter marked by mixed results, despite a slight positive surprise in operational profitability. The management attributed this decrease to several concurrent factors. The animal health business suffered from lackluster demand across its range of medications and vaccines. The pet segment recorded revenues of $1.65 billion for the quarter, up 3% year-over-year, but still falling short of internal targets. Concurrently, distributors showed reluctance to replenish their stocks, while an uncertain economic environment prompted consumers to cut back on animal health spending. The company also noted a decrease in veterinary visits, a key indicator of future demand. In terms of earnings, adjusted earnings per share stood at $1.70, exceeding the analysts' consensus of $1.62. Quarterly revenues reached $2.40 billion, slightly below expectations of $2.41 billion. The market gave little importance to this slight outperformance, focusing primarily on the downward revision of the full-year outlook.
